Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide in Type 2 Diabetes and Obesity
NCT07732218Phase 4Completed
- Sponsor
- Rehman Medical Institute
- Start
- Jul 2022
- Primary completion
- Mar 2023
- Countries
- 1
01
Overview
A Phase 4 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Rehman Medical Institute. Started Jul 2022; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07732218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07732218.